Franzone, Anna; Heg, Dik; Räber, Lorenz; Valgimigli, Marco; Piccolo, Raffaele; Zanchin, Thomas; Yamaji, Kyohei; Stortecky, Stefan; Blöchlinger, Stefan; Hunziker, Lukas; Praz, Fabien; Jüni, Peter; Windecker, Stephan; Pilgrim, Thomas (2016). External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clinical research in cardiology, 105(9), pp. 744-754. Springer-Medizin-Verlag 10.1007/s00392-016-0983-z
|
Text
Franzone ClinResCardiol 2016.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
|
|
Text
Franzone ClinResCardiol 2016_postprint.pdf - Accepted Version Available under License Publisher holds Copyright. Download (878kB) | Preview |
OBJECTIVES
We sought to systematically evaluate the external validity of a contemporary randomized controlled stent trial (BIOSCIENCE).
METHODS
Baseline characteristics and clinical outcomes of patients enrolled into the BIOSCIENCE trial at Bern University Hospital (n = 1216) were compared to those of patients included in the CARDIOBASE Bern PCI Registry at the same institution (n = 1045). The primary study endpoint was the rate of target lesion failure (TLF), defined as a composite of cardiac death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 year.
RESULTS
Women were underrepresented in the RCT compared to the registry (25 vs. 29.4 %, p = 0.020). Non-participants were older compared to study participants (69.2 ± 12.4 vs. 67.0 ± 11.6, p < 0.001), and had a higher prevalence of previous cerebrovascular events (10.8 vs. 5.2 %, p < 0.001), and chronic renal failure (35.5 vs. 15.6 %, p < 0.001). ST-segment elevation myocardial infarction (STEMI) and Killip class IV at presentation were more common among non-participants than participants (30.7 vs. 21.1 %, p < 0.001 and 7.8 vs. 0.4 %, p < 0.001, respectively). At 1 year, non-participants experienced a significantly higher rate of TLF, (15.0 vs. 6.5 %, p < 0.001), and patient-oriented composite endpoint (POCE), including death, MI or any repeat revascularization (21.6 vs. 11.2 %, p < 0.001). There was a significant interaction between POCE and presence or absence of an acute coronary syndrome in participants versus non-participants, respectively (p = 0.009).
CONCLUSIONS
Non-participants of this all-comers trial had a higher risk profile and adverse prognosis compared to study participants. Further efforts are needed to improve the external validity of contemporary RCTs.
Actions (login required)
 |
Edit item |